Phosphorylation of the ErbB3 binding protein Ebp1 by p21-activated kinase 1 in breast cancer cells

被引:20
作者
Akinmade, D. [1 ,2 ]
Talukder, A. H.
Zhang, Y. [1 ,2 ]
Luo, W-m [1 ]
Kumar, R. [3 ]
Hamburger, A. W. [1 ]
机构
[1] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21210 USA
[2] Univ Maryland, Dept Pathol, Baltimore, MD 21201 USA
[3] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
关键词
Ebp1; PA2G4; phosphorylation; PAK1; breast cancer;
D O I
10.1038/sj.bjc.6604261
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The ErbB3 binding protein ( Ebp1) is a transcriptional corepressor that inhibits the activity of proliferation- associated genes and the growth of human breast cancer cell lines. Treatment of breast cancer cells with the ErbB3 ligand heregulin ( HRG) results in increased phosphorylation of Ebp1 and transcriptional repression. The p21- activated serine/ threonine kinase 1 ( PAK1), which plays an important role in breast cancer progression and resistance to the anti- oestrogen tamoxifen, is also activated by HRG. We therefore examined the ability of PAK1 to phosphorylate and regulate the function of Ebp1. We found that PAK1 phosphorylated Ebp1 in vitro and mapped the phosphorylation site to threonine 261. Both HRG treatment and expression of a constitutively activated PAK1 in MCF- 7 breast cancer cells enhanced threonine phosphorylation of Ebp1. In MCF- 7 cells, ectopically expressed Ebp1 bound endogenous PAK1 and this association was enhanced by treatment with HRG. Mutation of the PAK1 phosphorylation site to glutamic acid, mimicking a phosphorylated state, completely abrogated the ability of Ebp1 to repress transcription, inhibit growth of breast cancer cell lines and contribute to tamoxifen sensitivity. These studies demonstrate for the first time that Ebp1 is a substrate of PAK1 and the importance of the PAK1 phosphorylation site for the functional activity of Ebp1 in breast cancer cells.
引用
收藏
页码:1132 / 1140
页数:9
相关论文
共 39 条
[11]   Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2 [J].
Jhabvala-Romero, F ;
Evans, A ;
Guo, SH ;
Denton, M ;
Clinton, GM .
ONCOGENE, 2003, 22 (50) :8178-8186
[12]   AUTOREGULATORY CONTROL OF E2F1 EXPRESSION IN RESPONSE TO POSITIVE AND NEGATIVE REGULATORS OF CELL-CYCLE PROGRESSION [J].
JOHNSON, DG ;
OHTANI, K ;
NEVINS, JR .
GENES & DEVELOPMENT, 1994, 8 (13) :1514-1525
[13]   Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer [J].
Johnston, SRD .
CLINICAL CANCER RESEARCH, 2006, 12 (03) :1061S-1068S
[14]  
King CC, 2000, METHOD ENZYMOL, V325, P315
[15]   ISOLATION AND CHARACTERIZATION OF ERBB3, A 3RD MEMBER OF THE ERBB/EPIDERMAL GROWTH-FACTOR RECEPTOR FAMILY - EVIDENCE FOR OVEREXPRESSION IN A SUBSET OF HUMAN MAMMARY-TUMORS [J].
KRAUS, MH ;
ISSING, W ;
MIKI, T ;
POPESCU, NC ;
AARONSON, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (23) :9193-9197
[16]   Emerging functions of p21-activated kinases in human cancer cells [J].
Kumar, R ;
Vadlamudi, RK .
JOURNAL OF CELLULAR PHYSIOLOGY, 2002, 193 (02) :133-144
[17]   p21-activated kinases in cancer [J].
Kumar, Rakesh ;
Gururaj, Anupama E. ;
Barnes, Christopher J. .
NATURE REVIEWS CANCER, 2006, 6 (06) :459-471
[18]   EXPRESSION OF THE ERBB3 GENE-PRODUCT IN BREAST-CANCER [J].
LEMOINE, NR ;
BARNES, DM ;
HOLLYWOOD, DP ;
HUGHES, CM ;
SMITH, P ;
DUBLIN, E ;
PRIGENT, SA ;
GULLICK, WJ ;
HURST, HC .
BRITISH JOURNAL OF CANCER, 1992, 66 (06) :1116-1121
[19]   Regulation of the ErbB3 binding protein Ebp1 by protein kinase C [J].
Lessor, TJ ;
Hamburger, AW .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2001, 175 (1-2) :185-191
[20]  
Lessor TJ, 2000, J CELL PHYSIOL, V183, P321, DOI 10.1002/(SICI)1097-4652(200006)183:3<321::AID-JCP4>3.0.CO